News

The multi-dose randomized Phase 2 study enrolled approximately 52 patients in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon. The study aims to investigate the safety

Pharmacyclics’ net loss was $10.96m for the fourth quarter ended 30 June 2011, compared to $6.84, for the same period in 2010. The company’s loss from operations were

Exonhit has reported net loss of EUR4.6m for the six months ended 30 June 2011, compared to EUR1.09m for the same period in 2010. For the six months

Avedro’s KXL, VibeX and Keraflex are CE marked and are commercially available outside of the US. Currently, the company has filed an additional application for orphan drug designation

Under the agreement, Frontage will combine its drug formulation and Bioanalytical analysis expertise with Spaulding Clinical’s Cardiac Safety and fully-automated Clinical Pharmacology facility. Spaulding Clinical will conduct all

BioData provides a lab management solution and allows the researchers to monitor materials, projects and experiments easily. LabLife was founded by Melina Fan, Benjie Chen and Kenneth Fan

As per the deal, both the firms will work together for identifying and characterizing biomarkers for drug development, drug discovery and diagnostics applications for range of therapeutic areas.

The filing of the NDA is backed by the results from a multicenter, two-cohort, single-arm, open-label Phase II Erivance BCC study that investigated vismodegib in patients with advanced

Esbriet is an orally active drug that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation and differentiation, and plays a key